fig3

Figure 3. Hsa-circ-0001030 suppresses TSCC tumor growth, metastasis, and enhances cisplatin sensitivity in vivo. (A) Representative bioluminescence images of orthotopic tongue xenografts derived from Cal27 cells stably overexpressing hsa-circ-0001030 or vector control (n = 5 per group); (B) Quantification of tumor radiance intensity in each group; (C) Representative photographs of excised tumors from the xenograft model; (D and E) Statistical analysis of tumor volume (D) and tumor weight (E) showing that hsa-circ-0001030 overexpression significantly suppressed tumor growth compared with the control group; (F) Representative in vivo bioluminescence images of the lung metastasis model (n = 5), indicating decreased metastatic signal intensity in the hsa-circ-0001030–overexpressing group; (G) Representative images of subcutaneous xenografts established with cisplatin-resistant Cal27R cells stably overexpressing hsa-circ-0001030; (H) Statistical analysis of tumor volume in Cal27R xenografts treated with cisplatin, demonstrating that hsa-circ-0001030 overexpression enhanced the antitumor efficacy of cisplatin in vivo. Data are presented as mean ± SD from five mice per group or three independent experiments. ^*P < 0.05; ^**P < 0.01; ^***P < 0.001. TSCC: Tongue squamous cell carcinoma; SD: standard deviation.